Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2003

01-02-2003 | Review

Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy

Authors: Wenlin Shao, Myles Brown

Published in: Breast Cancer Research | Issue 1/2003

Login to get access

Abstract

Estrogen receptor (ER) has a crucial role in normal breast development and is expressed in the most common breast cancer subtypes. Importantly, its expression is very highly predictive for response to endocrine therapy. Current endocrine therapies for ER-positive breast cancers target ER function at multiple levels. These include targeting the level of estrogen, blocking estrogen action at the ER, and decreasing ER levels. However, the ultimate effectiveness of therapy is limited by either intrinsic or acquired resistance. Identifying the factors and pathways responsible for sensitivity and resistance remains a challenge in improving the treatment of breast cancer. With a better understanding of coordinated action of ER, its coregulatory factors, and the influence of other intracellular signaling cascades, improvements in breast cancer therapy are emerging.
Literature
1.
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: the second decade. Cell. 1995, 83: 835-839.PubMedCrossRef
2.
Sommer S, Fuqua SA: Estrogen receptor and breast cancer. Semin Cancer Biol. 2001, 11: 339-352. 10.1006/scbi.2001.0389.PubMedCrossRef
3.
Turner RT, Riggs BL, Spelsberg TC: Skeletal effects of estrogen. Endocr Rev. 1994, 15: 275-300. 10.1210/er.15.3.275.PubMed
4.
Farhat MY, Lavigne MC, Ramwell PW: The vascular protective effects of estrogen. FASEB J. 1996, 10: 615-624.PubMed
5.
Beato M, Herrlich P, Schutz G: Steroid hormone receptors: many actors in search of a plot. [Review]. Cell. 1995, 83: 851-857.PubMedCrossRef
6.
Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E, Scrace G, Waterfield M, Chambon P: Cloning of the human oestrogen receptor cDNA. J Steroid Biochem. 1986, 24: 77-83. 10.1016/0022-4731(86)90035-X.PubMedCrossRef
7.
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996, 93: 5925-5930. 10.1073/pnas.93.12.5925.PubMedPubMedCentralCrossRef
8.
Mosselman S, Polman J, Dijkema R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392: 49-53. 10.1016/0014-5793(96)00782-X.PubMedCrossRef
9.
Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P: Functional domains of the human estrogen receptor. Cell. 1987, 51: 941-951.PubMedCrossRef
10.
11.
Glass CK: Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr Rev. 1994, 15: 391-407. 10.1210/er.15.3.391.PubMed
12.
Aumais JP, Lee HS, DeGannes C, Horsford J, White JH: Function of directly repeated half-sites as response elements for steroid hormone receptors. J Biol Chem. 1996, 271: 12568-12577. 10.1074/jbc.271.42.25727.PubMedCrossRef
13.
Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000, 74: 311-317. 10.1016/S0960-0760(00)00108-4.PubMedCrossRef
14.
Kushner PJ, Agard D, Feng WJ, Lopez G, Schiau A, Uht R, Webb P, Greene G: Oestrogen receptor function at classical and alternative response elements. Novartis Found Symp. 2000, 230: 20-26. 10.1002/0470870818.ch3. discussion 27–40PubMedCrossRef
15.
Hall JM, Couse JF, Korach KS: The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001, 276: 36869-36872. 10.1074/jbc.R100029200.PubMedCrossRef
16.
Rosenfeld MG, Glass CK: Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem. 2001, 276: 36865-36868. 10.1074/jbc.R100041200.PubMedCrossRef
17.
Kingston RE, Narlikar GJ: ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev. 1999, 13: 2339-2352. 10.1101/gad.13.18.2339.PubMedCrossRef
18.
DiRenzo J, Shang Y, Phelan M, Sif S, Myers M, Kingston R, Brown M: BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Biol. 2000, 20: 7541-7549. 10.1128/MCB.20.20.7541-7549.2000.PubMedPubMedCentralCrossRef
19.
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996, 87: 953-959.PubMedCrossRef
20.
Ogryzko VV, Kotani T, Zhang X, Schlitz RL, Howard T, Yang XJ, Howard BH, Qin J, Nakatani Y: Histone-like TAFs within the PCAF histone acetylase complex. Cell. 1998, 94: 35-44.PubMedCrossRef
21.
Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y: A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature. 1996, 382: 319-324. 10.1038/382319a0.PubMedCrossRef
22.
Onate SA, Tsai SY, Tsai MJ, O'Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995, 270: 1354-1357.PubMedCrossRef
23.
Hong H, Kohli K, Garabedian MJ, Stallcup M: GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol. 1997, 17: 2735-2744.PubMedPubMedCentralCrossRef
24.
Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H: TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 1996, 15: 3667-3675.PubMedPubMedCentral
25.
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997, 277: 965-968. 10.1126/science.277.5328.965.PubMedCrossRef
26.
Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Prival-sky ML, Nakatani Y, Evans RM: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997, 90: 569-580.PubMedCrossRef
27.
Li H, Gomes PJ, Chen JD: RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA. 1997, 94: 8479-8484. 10.1073/pnas.94.16.8479.PubMedPubMedCentralCrossRef
28.
Suen CS, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE: A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem. 1998, 273: 27645-27653. 10.1074/jbc.273.42.27645.PubMedCrossRef
29.
Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW: TRAM-1, A novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem. 1997, 272: 27629-27634. 10.1074/jbc.272.44.27629.PubMedCrossRef
30.
Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG: The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 1997, 387: 677-684. 10.1038/42652.PubMedCrossRef
31.
Heery DM, Kalkhoven E, Hoare S, Parker MG: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997, 387: 733-736. 10.1038/42750.PubMedCrossRef
32.
Chen D, Huang SM, Stallcup MR: Synergistic p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. J Biol Chem. 2000, 275: 40810-40816. 10.1074/jbc.M005459200.PubMedCrossRef
33.
Misiti S, Schomburg L, Yen PM, Chin WW: Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology. 1998, 139: 2493-2500. 10.1210/en.139.5.2493.PubMedCrossRef
34.
Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, Szeto D, Gleiberman A, Krones A, Pratt K, Rosenfeld R, Glass CK, Rosenfeld MG: Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci USA. 2000, 97: 13549-13554. 10.1073/pnas.260463097.PubMedPubMedCentralCrossRef
35.
Lauritsen KJ, List HJ, Reiter R, Wellstein A, Riegel AT: A role for TGF-β in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene. 2002, 21: 7147-7155. 10.1038/sj.onc.1205943.PubMedCrossRef
36.
Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW: Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science. 1998, 279: 1922-1925. 10.1126/science.279.5358.1922.PubMedCrossRef
37.
Nishihara E, Yoshida-Komiya H, Chan CS, Liao L, Davis RL, O'Malley BW, Xu J: SRC-1 null mice exhibit moderate motor dysfunction and delayed development of cerebellar Purkinje cells. J Neurosci. 2003, 23: 213-222.PubMed
38.
Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley BW: The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA. 2000, 97: 6379-6384. 10.1073/pnas.120166297.PubMedPubMedCentralCrossRef
39.
Burakov D, Wong CW, Rachez C, Cheskis BJ, Freedman LP: Functional interactions between the estrogen receptor and DRIP205, a subunit of the heteromeric DRIP coactivator complex. J Biol Chem. 2000, 275: 20928-20934. 10.1074/jbc.M002013200.PubMedCrossRef
40.
Kang YK, Guermah M, Yuan CX, Roeder RG: The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc Natl Acad Sci USA. 2002, 99: 2642-2647. 10.1073/pnas.261715899.PubMedPubMedCentralCrossRef
41.
Warnmark A, Almlof T, Leers J, Gustafsson JA, Treuter E: Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERα and ERβ. J Biol Chem. 2001, 276: 23397-23404. 10.1074/jbc.M011651200.PubMedCrossRef
42.
Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998, 92: 829-839.PubMedCrossRef
43.
Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP: Modulation of estrogen receptor-α transcriptional activity by the coactivator PGC-1. J Biol Chem. 2000, 275: 16302-16308. 10.1074/jbc.M001364200.PubMedCrossRef
44.
Saville B, Poukka H, Wormke M, Janne OA, Palvimo JJ, Stoner M, Samudio I, Safe S: Cooperative coactivation of estrogen receptor α in ZR-75 human breast cancer cells by SNURF and TATA-binding protein. J Biol Chem. 2002, 277: 2485-2497. 10.1074/jbc.M109021200.PubMedCrossRef
45.
Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A, Kumar R: Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem. 2001, 276: 38272-38279.PubMed
46.
Shao W, Halachmi S, Brown M: ERAP140, a conserved tissue-specific nuclear receptor coactivator. Mol Cell Biol. 2002, 22: 3358-3372. 10.1128/MCB.22.10.3358-3372.2002.PubMedPubMedCentralCrossRef
47.
Chang C, Norris JD, Gron H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP: Dissection of the LXXLL nuclear receptor–coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors α and β. Mol Cell Biol. 1999, 19: 8226-8239.PubMedPubMedCentralCrossRef
48.
Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ, O'Malley BW: A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell. 1999, 97: 17-27.PubMedCrossRef
49.
Endoh H, Maruyama K, Masuhiro Y, Kobayashi Y, Goto M, Tai H, Yanagisawa J, Metzger D, Hashimoto S, Kato S: Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor α. Mol Cell Biol. 1999, 19: 5363-5372.PubMedPubMedCentralCrossRef
50.
Watanabe M, Yanagisawa J, Kitagawa H, Takeyama K, Ogawa S, Arao Y, Suzawa M, Kobayashi Y, Yano T, Yoshikawa H, Masuhiro Y, Kato S: A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor α coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J. 2001, 20: 1341-1352. 10.1093/emboj/20.6.1341.PubMedPubMedCentralCrossRef
51.
Ko L, Cardona GR, Henrion-Caude A, Chin WW: Identification and characterization of a tissue-specific coactivator, GT198, that interacts with the DNA-binding domains of nuclear receptors. Mol Cell Biol. 2002, 22: 357-369. 10.1128/MCB.22.1.357-369.2002.PubMedPubMedCentralCrossRef
52.
Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997, 88: 405-415.PubMedCrossRef
53.
Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME: Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol. 1997, 17: 5338-5347.PubMedPubMedCentralCrossRef
54.
McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME: P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA. 1999, 96: 5382-5387. 10.1073/pnas.96.10.5382.PubMedPubMedCentralCrossRef
55.
Lamb J, Ladha MH, McMahon C, Sutherland RL, Ewen ME: Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol. 2000, 20: 8667-8675. 10.1128/MCB.20.23.8667-8675.2000.PubMedPubMedCentralCrossRef
56.
Li Z, Joyal JL, Sacks DB: Calmodulin enhances the stability of the estrogen receptor. J Biol Chem. 2001, 276: 17354-17360. 10.1074/jbc.M010238200.PubMedCrossRef
57.
Fan M, Long X, Bailey JA, Reed CA, Osborne E, Gize EA, Kirk EA, Bigsby RM, Nephew KP: The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol. 2002, 16: 315-330. 10.1210/me.16.2.315.PubMedCrossRef
58.
Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F: Cross-talk between transforming growth factor-β and estrogen receptor signaling through Smad3. J Biol Chem. 2001, 276: 42908-42914. 10.1074/jbc.M105316200.PubMedCrossRef
59.
Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA. 2002, 99: 14783-14788. 10.1073/pnas.192569699.PubMedPubMedCentralCrossRef
60.
Chen JD, Evans RM: A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995, 377: 454-457. 10.1038/377454a0.PubMedCrossRef
61.
Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 1995, 377: 397-404. 10.1038/377397a0.PubMedCrossRef
62.
Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000, 103: 843-852.PubMedCrossRef
63.
Huang HJ, Norris JD, McDonnell DP: Identification of a negative regulatory surface within estrogen receptor α provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol Endocrinol. 2002, 16: 1778-1792. 10.1210/me.2002-0089.PubMedCrossRef
64.
Webb P, Nguyen P, Kushner PJ: Differential SERM effects on corepressor binding dictate ERα activity in vivo. J Biol Chem. 2003, 278: 6912-6920. 10.1074/jbc.M208501200.PubMedCrossRef
65.
Wei LN, Hu X, Chandra D, Seto E, Farooqui M: Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing. J Biol Chem. 2000, 275: 40782-40787. 10.1074/jbc.M004821200.PubMedCrossRef
66.
Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV: Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol. 2000, 14: 369-381. 10.1210/me.14.3.369.PubMedCrossRef
67.
Johansson L, Thomsen JS, Damdimopoulos AE, Spyrou G, Gustafsson JA, Treuter E: The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ERα and ERβ. J Biol Chem. 1999, 274: 345-353. 10.1074/jbc.274.1.345.PubMedCrossRef
68.
Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS: An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA. 1999, 96: 6947-6952. 10.1073/pnas.96.12.6947.PubMedPubMedCentralCrossRef
69.
Zhang H, Thomsen JS, Johansson L, Gustafsson JA, Treuter E: DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. J Biol Chem. 2000, 275: 39855-39859. 10.1074/jbc.C000567200.PubMedCrossRef
70.
Moras D, Gronemeyer H: The nuclear receptor ligand-binding domain: structure and function. urr Opin Cell Biol. 1998, 10: 384-391. 10.1016/S0955-0674(98)80015-X.CrossRef
71.
Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997, 389: 753-758. 10.1038/39645.PubMedCrossRef
72.
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998, 95: 927-937.PubMedCrossRef
73.
Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M: Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18: 4608-4618. 10.1093/emboj/18.17.4608.PubMedPubMedCentralCrossRef
74.
Pike AC, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li YL, Gustafsson JA, Carlquist M: Structural insights into the mode of action of a pure antiestrogen. Structure (Camb). 2001, 9: 145-153. 10.1016/S0969-2126(01)00568-8.CrossRef
75.
Danielian PS, White R, Lees JA, Parker MG: Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 1992, 11: 1025-1033.PubMedPubMedCentral
76.
Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR: Structure and specificity of nuclear receptor–coactivator interactions. Genes Dev. 1998, 12: 3343-3356.PubMedPubMedCentralCrossRef
77.
Smith CL: Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod. 1998, 58: 627-632.PubMedCrossRef
78.
Segars JH, Driggers PH: Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol Metab. 2002, 13: 349-354. 10.1016/S1043-2760(02)00633-1.PubMedPubMedCentralCrossRef
79.
Driggers PH, Segars JH: Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab. 2002, 13: 422-427. 10.1016/S1043-2760(02)00634-3.PubMedPubMedCentralCrossRef
80.
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995, 270: 1491-1494.PubMedCrossRef
81.
Bunone G, Briand P-A, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15: 2174-2183.PubMedPubMedCentral
82.
Joel PB, Traish AM, Lannigan DA: Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem. 1998, 273: 13317-13323. 10.1074/jbc.273.21.13317.PubMedCrossRef
83.
Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, Ali : Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell. 2000, 6: 127-137.PubMedCrossRef
84.
Aronica SM, Katzenellenbogen BS: Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol. 1993, 7: 743-752. 10.1210/me.7.6.743.PubMed
85.
Cho H, Aronica SM, Katzenellenbogen BS: Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3',5'-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology. 1994, 134: 658-664. 10.1210/en.134.2.658.PubMed
86.
Chen D, Pace PE, Coombes RC, Ali S: Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. Mol Cell Biol. 1999, 19: 1002-1015.PubMedPubMedCentralCrossRef
87.
Rowan BG, Weigel NL, O'Malley BW: Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem. 2000, 275: 4475-4483. 10.1074/jbc.275.6.4475.PubMedCrossRef
88.
Font de Mora J, Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 2000, 20: 5041-5047. 10.1128/MCB.20.14.5041-5047.2000.PubMedPubMedCentralCrossRef
89.
Janknecht R, Nordheim A: MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. Biochem Biophys Res Commun. 1996, 228: 831-837. 10.1006/bbrc.1996.1740.PubMedCrossRef
90.
Liu YZ, Chrivia JC, Latchman DS: Nerve growth factor up-regulates the transcriptional activity of CBP through activation of the p42/p44(MAPK) cascade. J Biol Chem. 1998, 273: 32400-32407. 10.1074/jbc.273.49.32400.PubMedCrossRef
91.
Gusterson R, Brar B, Faulkes D, Giordano A, Chrivia J, Latchman D: The transcriptional co-activators CBP and p300 are activated via phenylephrine through the p42/p44 MAPK cascade. J Biol Chem. 2002, 277: 2517-2524. 10.1074/jbc.M104626200.PubMedCrossRef
92.
Ait-Si-Ali S, Carlisi D, Ramirez S, Upegui-Gonzalez LC, Duquet A, Robin P, Rudkin B, Harel-Bellan A, Trouche D: Phosphorylation by p44 MAP kinase/ERK1 stimulates CBP histone acetyl transferase activity in vitro. Biochem Biophys Res Commun. 1999, 262: 157-162. 10.1006/bbrc.1999.1132.PubMedCrossRef
93.
Redeuilh G, Attia A, Mester J, Sabbah MP: Transcriptional activation by the oestrogen receptor α is modulated through inhibition of cyclin-dependent kinases. Oncogene. 2002, 21: 5773-5782. 10.1038/sj.onc.1205753.PubMedCrossRef
94.
Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000, 407: 538-541. 10.1038/35035131.PubMedPubMedCentralCrossRef
95.
Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001, 104: 719-730.PubMed
96.
Jensen EV, Jacobson HI: Basic guides to the mechanism of estrogen action. Recent Prog Horm Res. 1962, 18: 387-414.
97.
Speirs V: Oestrogen receptor β in breast cancer: good, bad or still too early to tell?. J Pathol. 2002, 197: 143-147. 10.1002/path.1072.PubMedCrossRef
98.
Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997, 57: 4987-4991.PubMed
99.
Fuqua SA: The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2001, 6: 407-417. 10.1023/A:1014782813943.PubMedCrossRef
100.
Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, Chang MN, Bisel HF, Windschitl HE, Twito DI: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol. 1986, 4: 178-185.PubMed
101.
Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986, 4: 1326-1330.PubMed
102.
Buzdar A: An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer. Eur J Cancer. 2000, 36 (Suppl 4): S82-S84.PubMedCrossRef
103.
Buzdar AU: New generation aromatase inhibitors – from the advanced to the adjuvant setting. Breast Cancer Res Treat. 2002, 75 (Suppl 1): S13-S17. 10.1023/A:1020305615033. discussion S33–S35PubMedCrossRef
104.
Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998, 83: 1142-1152. 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7.PubMedCrossRef
105.
Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998, 16: 453-461.PubMed
106.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G: Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clin Breast Cancer. 2000, 1 (Suppl 1): S15-S18.PubMedCrossRef
107.
Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001, 19: 3357-3366.PubMed
108.
Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001, 92: 2247-2258. 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y.PubMedCrossRef
109.
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001, 19: 2596-2606.PubMed
110.
Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002, 359: 2131-2139. 10.1016/S0140-6736(02)09088-8.PubMedCrossRef
111.
Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896, 2: 104-107.CrossRef
112.
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef
113.
Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998, 339: 1609-1618. 10.1056/NEJM199811263392207.PubMedCrossRef
114.
Wickerham L: Tamoxifen – an update on current data and where it can now be used. Breast Cancer Res Treat. 2002, 75 (Suppl 1): S7-S12. 10.1023/A:1020353530963. discussion S33–S35PubMedCrossRef
115.
Group EBCTC: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Part 1. Lancet. 1992, 339: 1-15. 10.1016/0140-6736(92)90139-T.
116.
Group EBCTC: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Part 2. Lancet. 1992, 339: 71-85. 10.1016/0140-6736(92)90997-H.
117.
Rusthoven JJ: The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. Eur J Cancer. 1998, 34 (Suppl 3): S31-S36.PubMedCrossRef
118.
Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J, Rutgvist LE, Glass U, Silfversward C, Somell A, Wilking N, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989, 333: 117-120. 10.1016/S0140-6736(89)91141-0.CrossRef
119.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.PubMedCrossRef
120.
Wolmark N, Dunn BK: The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann N Y Acad Sci. 2001, 949: 99-108.PubMedCrossRef
121.
Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T, IBIS investigators: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002, 360: 817-824. 10.1016/S0140-6736(02)09962-2.PubMedCrossRef
122.
Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I, Mouridsen HT: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994, 12: 992-997.PubMed
123.
Grey AB, Stapleton JP, Evans MC, Reid IR: The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995, 80: 3191-3195. 10.1210/jc.80.11.3191.PubMed
124.
Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR: The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med. 1995, 99: 636-641. 10.1016/S0002-9343(99)80251-4.PubMedCrossRef
125.
Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994, 86: 1534-1539. 10.1093/jnci/86.20.1534.PubMedCrossRef
126.
Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I: Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol. 1996, 14: 429-433.PubMed
127.
Jordan VC, Dowse LJ: Tamoxifen as an anti-tumour agent: effect on oestrogen binding. J Endocrinol. 1976, 68: 297-303.PubMedCrossRef
128.
Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science. 2002, 295: 2465-2468. 10.1126/science.1068537.PubMedCrossRef
129.
Perry RR, Kang Y, Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent and-independent human breast cancer cells. Ann Surg Oncol. 1995, 2: 238-245.PubMedCrossRef
130.
Gelmann EP: Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog?. J Natl Cancer Inst. 1996, 88: 224-226.PubMedCrossRef
131.
Cameron DA, Ritchie AA, Langdon S, Anderson TJ, Miller WR: Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res Treat. 1997, 45: 99-107. 10.1023/A:1005850827825.PubMedCrossRef
132.
Budtz PE: Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen. Cell Prolif. 1999, 32: 289-302. 10.1046/j.1365-2184.1999.3250289.x.PubMedCrossRef
133.
Cameron DA, Keen JC, Dixon JM, Bellamy C, Hanby A, Anderson TJ, Miller WR: Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur J Cancer. 2000, 36: 845-851. 10.1016/S0959-8049(00)00013-7.PubMedCrossRef
134.
Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994, 86: 527-537. 10.1093/jnci/86.7.527.PubMedCrossRef
135.
Assikis VJ, Jordan VC: Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet. 1995, 49: 241-257. 10.1016/0020-7292(95)02387-R.PubMedCrossRef
136.
Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997, 11: 657-666. 10.1210/me.11.6.657.PubMedCrossRef
137.
Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR, Kushner PJ: Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol. 1998, 12: 1605-1618. 10.1210/me.12.10.1605.PubMedCrossRef
138.
Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA. 1998, 95: 2920-2925. 10.1073/pnas.95.6.2920.PubMedPubMedCentralCrossRef
139.
Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E, Hedrick SM, Mandel G, Glass CK, Rose DW, Rosenfeld MG: Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell. 2000, 102: 753-763.PubMedCrossRef
140.
Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK: Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol. 2003, 17: 1543-1554. 10.1210/me.2001-0144.PubMedCrossRef
141.
Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H, Hayashi S: Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol. 2002, 192: 93-104. 10.1016/S0303-7207(02)00086-2.PubMedCrossRef
142.
Curtis MG: Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention. Drug Saf. 2001, 24: 1039-1053.PubMedCrossRef
143.
Pukkala E, Kyyronen P, Sankila R, Holli K: Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. Int J Cancer. 2002, 100: 337-341. 10.1002/ijc.10454.PubMedCrossRef
144.
Holli K: Tamoxifen versus toremifene in the adjuvant treatment of breast cancer. Eur J Cancer. 2002, 38 (Suppl 6): S37-S38.PubMedCrossRef
145.
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999, 281: 2189-2197. 10.1001/jama.281.23.2189.PubMedCrossRef
146.
Jubelirer SJ, Crowell EB: The STAR (Study of Tamoxifen And Raloxifene) trial in West Virginia. W V Med J. 2000, 96: 602-604.PubMed
147.
Jordan VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem. 2003, 46: 883-908. 10.1021/jm020449y.PubMedCrossRef
148.
Jordan VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem. 2003, 46: 1081-1111. 10.1021/jm020450x.PubMedCrossRef
149.
Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS: Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol. 1996, 10: 119-131. 10.1210/me.10.2.119.PubMed
150.
Dutertre M, Smith CL: Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 2000, 295: 431-437.PubMed
151.
Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 1997, 277: 1508-1510. 10.1126/science.277.5331.1508.PubMedCrossRef
152.
Jones PS, Parrott E, White IN: Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent. J Biol Chem. 1999, 274: 32008-32014. 10.1074/jbc.274.45.32008.PubMedCrossRef
153.
Hall JM, McDonnell DP: The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999, 140: 5566-5578. 10.1210/en.140.12.5566.PubMed
154.
Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 1995, 55: 3331-3338.PubMed
155.
Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P, Theillet C: In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res. 1998, 4: 2925-2929.PubMed
156.
List HJ, Reiter R, Singh B, Wellstein A, Riegel AT: Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat. 2001, 68: 21-28. 10.1023/A:1017910924390.PubMedCrossRef
157.
Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/ neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003, 95: 353-361. 10.1093/jnci/95.5.353.PubMedCrossRef
158.
Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bieche I: Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res. 2003, 9: 1259-1266.PubMed
159.
Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992, 13: 3-17. 10.1210/er.13.1.3.PubMed
160.
Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL, Foekens JA: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat. 1994, 29: 73-83.PubMedCrossRef
161.
Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME: Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 2000, 60: 3081-3087.PubMed
162.
Spigel DR, Burstein HJ: HER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol. 2002, 3: 163-174.PubMedCrossRef
163.
Nahta R, Hortobagyi GN, Esteva FJ: Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist. 2003, 8: 5-17.PubMedCrossRef
164.
Morris C: The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat. 2002, 75 (Suppl 1): S51-S55. 10.1023/A:1020370018668. discussion S57–S59PubMedCrossRef
165.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.PubMedCrossRef
166.
Klijn JG, Setyono-Han B, Foekens JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000, 65: 825-830. 10.1016/S0039-128X(00)00195-1.PubMedCrossRef
167.
Ueda H, Takenawa T, Millan JC, Gesell MS, Brandes D: The effects of retinoids on proliferative capacities and macromolecular synthesis in human breast cancer MCF-7 cells. Cancer. 1980, 46: 2203-2209.PubMedCrossRef
168.
Fontana JA, Miksis G, Miranda DM, Durham JP: Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds. J Natl Cancer Inst. 1987, 78: 1107-1112.PubMed
169.
Fontana JA, Hobbs PD, Dawson MI: Inhibition of mammary carcinoma growth by reinoidal benzoic acid derivatives. Exp Cell Biol. 1988, 56: 254-263.PubMed
170.
Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM: A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther. 2002, 1: 1009-1017.PubMed
171.
Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, Sporn MB: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999, 91: 1847-1856. 10.1093/jnci/91.21.1847.PubMedCrossRef
172.
Bortman P, Folgueira MA, Katayama ML, Snitcovsky IM, Brentani MM: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. Braz J Med Biol Res. 2002, 35: 1-9.PubMedCrossRef
173.
Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 2003, 9: 1-9.PubMed
174.
Stoll BA: Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention. Eur J Cancer Prev. 2002, 11: 319-325. 10.1097/00008469-200208000-00002.PubMedCrossRef
Metadata
Title
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
Authors
Wenlin Shao
Myles Brown
Publication date
01-02-2003
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2003
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr742

Other articles of this Issue 1/2003

Breast Cancer Research 1/2003 Go to the issue

Commentary

Models of breast cancer: quo vadis, animal modeling?

Commentary

Models of breast cancer: is merging human and animal models the future?

Research article

Interleukin-2 and its receptor complex (α, β and γ chains) in in situand infiltrative human breast cancer: an immunohistochemical comparative study

Meeting report

AACR Special Conference: Advances in Breast Cancer Research – Genetics, Biology, and Clinical Implications, Huntington Beach, California, USA, 8–12 October 2003

Research article

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

Research article

Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits